Piper Sandler on MiniMed Group (MMED): 'Nice Start as a Public Entity but Still Plenty to Prove'
Tweet Send to a Friend
Piper Sandler analyst Matt O'Brien reiterated a Neutral rating and $16.00 price target on MiniMed Group (NASDAQ: MMED).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
